Long-term survival following a phase I/II trial with VETOPEC for solid tumors in childhood

Journal of Pediatric Hematology/Oncology

Volumn 28, Issue 1, 2006, Pages 40-42

  Ziegler, David S ^a,b   McCowage, Geoffrey ^c   Cohn, Richard J ^a,b   White, Les ^a,b  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Childhood; Late effects; Phase I; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; VETOPEC PROTOCOL;

CANCER GROWTH; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; FOLLOW UP; HEALTH STATUS; HEARING LOSS; HUMAN; MAJOR CLINICAL STUDY; NEUROBLASTOMA; OVARY INSUFFICIENCY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; REVIEW; SOLID TUMOR; SURVIVAL TIME; TIME SERIES ANALYSIS; UNSPECIFIED SIDE EFFECT; ADULT; ARTICLE; INFANT; MEDICAL RECORD; MORTALITY; NEOPLASM; PRESCHOOL CHILD; SURVIVAL RATE; TIME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CYCLOPHOSPHAMIDE; ETOPOSIDE; FOLLOW-UP STUDIES; HUMANS; INFANT; MEDICAL RECORDS; NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TIME FACTORS; VINCRISTINE;

EID: 33644842431     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. White L, McCowage G, Kannourakis G, et al. Dose-intensive cyclophosphamide with etoposide and vincristine for pediatric solid tumors: a phase I/II pilot study by the Australia and New Zealand Childhood Cancer Study Group. J Clin Oncol. 1994;12:522-531.
2. Allen JC, Helson L. High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg. 1981;55:749-756.
3. Friedman HS, Mahaley MS, Schold SC, et al. Efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastoma. Neurosurgery. 1986;18:335-340.
4. Mitchell CD, Dangio GJ. Does cyclophosphamide improve survival rates in patients with solid tumors? Am J Clin Oncol Cancer Clin Trials. 1986;9:277-280.
5. Strother D, Ashley D, Kellie SJ, et al. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. J Clin Oncol. 2001;19:2696-2704.
6. Bramwell VH, Mouridsen HT, Santoro A, et al. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol. 1987;23:311-321.
7. Lilley ER, Rosenberg MC, Elion GB, et al. Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft. Cancer Res. 1990;50:284-287.
8. Kalwinsky DK, Dahl GV, Mirro J Jr, et al. Cyclophosphamide/etoposide: effective reinduction therapy for children with acute nonlymphocytic leukemia in relapse. Cancer Treat Rep. 1985;69:887-889.
9. Saleh RA, Graham-Pole J, Cassano W, et al. Response of osteogenic sarcoma to the combination of etoposide and cyclophosphamide as neoadjuvant chemotherapy. Cancer. 1990;65:861-865.
10. Spitzer TR, Cottler-Fox M, Torrisi J, et al. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation. Bone Marrow Transplant. 1989;4:559-565.
11. Selawry OS, Holland JF, Wolman IJ. Effect of vincristine (NSC-67574) on malignant solid tumors in children. Cancer Chemother Rep. 1968;52:497-500.
12. Shah S, Weitman S, Langevin AM, et al. Phase I therapy trials in children with cancer. J Pediatr Hematol Oncol. 1998;20:431-438.
13. Weitman S, Ochoa S, Sullivan J, et al. Pediatric phase II cancer chemotherapy trials: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 1997:20:187-191.
14. Carpenter PA, White L, McCowage GB, et al. A dose-intensive, cyclophosphamide-based regimen for the treatment of recurrent/progressive or advanced solid tumors of childhood: a report from the Australia and New Zealand Children's Cancer Study Group. Cancer. 1997;80:489-496.
15. Horstmann E, McCabe MS, Grochow L, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med. 2005;352:895-904.
16. Grundy P, Breslow N, Green DM, et al. Prognostic factors for children with recurrent Wilms tumor: results from the Second and Third National Wilms Tumor Study. J Clin Oncol. 1989;7:638-647.
17. Grundy PE, Green D, Coppes MJ, et al. Renal Tumors. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology, 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:865-893.
18. Ziegler DS, Cohn RJ, McCowage GB, et al. Efficacy of vincristine and etoposide with high-dose cyclophosphamide (VETOPEC) in very high risk pediatric brain tumours. 11th International Symposium on Pediatric Neuro-Oncology, 2004.
19. Lal A, White L, Mongrovius R, et al. Intensive cyclophosphamide-based sequential regimen followed by autologous peripheral blood stem cells (PBSC) and filgrastim in poor-risk childhood solid tumors (VETOPEC II): a phase I/II trial of the Australian and New Zealand Children's Cancer Study Group. 1999 ASCO annual meeting. Abstract 2205.